Cargando…
Prediction of Ventricular Arrhythmias by QRS/QTc - Ratio in Citalopram or Escitalopram Intoxication
BACKGROUND: The U.S. Food and Drug Administration (FDA) has stated that citalopram and escitalopram should not be used at daily doses above 40 mg/20 mg due to risk for development of fatal ventricular arrhythmias like torsade de pointes (TdP). Yet, supratherapeutic serum concentrations of citalopram...
Autores principales: | Dietrichs, Erik Sveberg, Smith, Godfrey L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966227/ https://www.ncbi.nlm.nih.gov/pubmed/35372426 http://dx.doi.org/10.3389/fmed.2022.866454 |
Ejemplares similares
-
Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
por: Faraj, Pari, et al.
Publicado: (2023) -
Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study
por: Qirjazi, Elena, et al.
Publicado: (2016) -
Rise of escitalopram and the fall of citalopram
por: Cavanah, Luke R., et al.
Publicado: (2023) -
Evaluation of QTc prolongation and dosage effect with citalopram
por: McClelland, Justine, et al.
Publicado: (2016) -
Is hypothermia more neuroprotective than avoiding fever after cardiac arrest?
por: Dietrichs, Erik Sveberg, et al.
Publicado: (2021)